Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Abstract Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Measures Team aimed to establish a harmonized clinical...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Schizophrenia |
| Online Access: | https://doi.org/10.1038/s41537-025-00556-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765455551528960 |
|---|---|
| author | Jean Addington Lu Liu Amy Braun Andrea Auther Monica E. Calkins Barbara A. Cornblatt Cheryl M. Corcoran Paolo Fusar-Poli Melissa J. Kerr Catalina V. Mourgues-Codern Angela R. Nunez Dominic Oliver Gregory P. Strauss Barbara C. Walsh Luis K. Alameda Celso Arango Nicholas J. K. Breitborde Matthew R. Broome Kristin S. Cadenhead Ricardo E. Carrion Eric Yu Hai Chen Jimmy Choi Michael J. Coleman Philippe Conus Covadonga M. Diaz-Caneja Dominic Dwyer Lauren M. Ellman Masoomeh Faghankhani Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Hui Grace R. Jacobs Joseph Kambeitz Lana Kambeitz-Ilankovic Matcheri S. Keshavan Sung-Wan Kim Nikolaos Koutsouleris Jun Soo Kwon Kerstin Langbein Kathryn E. Lewandowski Daniel Mamah Patricia J. Marcy Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Nora Penzel Jesus Perez Diana O. Perkins Albert R. Powers Jack Rogers Fred W. Sabb Jason Schiffman Jai L. Shah Steven M. Silverstein Stefan Smesny William S. Stone Andrew Thompson Judy L. Thompson Rachel Upthegrove Swapna Verma Jijun Wang Heather M. Wastler Alana Wickham Inge Winter-van Rossum Daniel H. Wolf Sylvain Bouix Ofer Pasternak Rene S. Kahn Carrie E. Bearden John M. Kane Patrick D. McGorry Kate Buccilli Barnaby Nelson Martha E. Shenton Scott W. Woods the Accelerating Medicines Partnership® -Schizophrenia Alison R. Yung |
| author_facet | Jean Addington Lu Liu Amy Braun Andrea Auther Monica E. Calkins Barbara A. Cornblatt Cheryl M. Corcoran Paolo Fusar-Poli Melissa J. Kerr Catalina V. Mourgues-Codern Angela R. Nunez Dominic Oliver Gregory P. Strauss Barbara C. Walsh Luis K. Alameda Celso Arango Nicholas J. K. Breitborde Matthew R. Broome Kristin S. Cadenhead Ricardo E. Carrion Eric Yu Hai Chen Jimmy Choi Michael J. Coleman Philippe Conus Covadonga M. Diaz-Caneja Dominic Dwyer Lauren M. Ellman Masoomeh Faghankhani Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Hui Grace R. Jacobs Joseph Kambeitz Lana Kambeitz-Ilankovic Matcheri S. Keshavan Sung-Wan Kim Nikolaos Koutsouleris Jun Soo Kwon Kerstin Langbein Kathryn E. Lewandowski Daniel Mamah Patricia J. Marcy Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Nora Penzel Jesus Perez Diana O. Perkins Albert R. Powers Jack Rogers Fred W. Sabb Jason Schiffman Jai L. Shah Steven M. Silverstein Stefan Smesny William S. Stone Andrew Thompson Judy L. Thompson Rachel Upthegrove Swapna Verma Jijun Wang Heather M. Wastler Alana Wickham Inge Winter-van Rossum Daniel H. Wolf Sylvain Bouix Ofer Pasternak Rene S. Kahn Carrie E. Bearden John M. Kane Patrick D. McGorry Kate Buccilli Barnaby Nelson Martha E. Shenton Scott W. Woods the Accelerating Medicines Partnership® -Schizophrenia Alison R. Yung |
| author_sort | Jean Addington |
| collection | DOAJ |
| description | Abstract Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Measures Team aimed to establish a harmonized clinical assessment protocol across these two research networks and to define ascertainment criteria and primary and secondary endpoints. In addition to developing the assessment protocol, the goals of this aspect of the AMP SCZ project were: (1) to implement and monitor clinical training, ascertainment of participants, and clinical assessments; (2) to provide expert clinical input to the Psychosis Risk Evaluation, Data Integration and Computational Technologies: Data Processing, Analysis, and Coordination Center (PREDICT-DPACC) for data collection, quality control, and preparation of data for the analysis of the clinical measures; and (3) to provide ongoing support to the collection, analysis, and reporting of clinical data. This paper describes the (1) protocol clinical endpoints and outcomes, (2) rationale for the selection of the clinical measures, (3) extensive training of clinical staff, (4) preparation of clinical measures for a multisite study which includes several sites where English is not the native language; and (5) the assessment of measure stability over time in the AMP SCZ observational study comparing clinical ratings at baseline and at the 2-month follow up. Watch Dr. Jean Addington discuss her work and this article: https://vimeo.com/1040425281 . |
| format | Article |
| id | doaj-art-eecd2f9551414721b4ed2ee606eed59f |
| institution | DOAJ |
| issn | 2754-6993 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Schizophrenia |
| spelling | doaj-art-eecd2f9551414721b4ed2ee606eed59f2025-08-20T03:04:51ZengNature PortfolioSchizophrenia2754-69932025-04-0111111010.1038/s41537-025-00556-7Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington0Lu Liu1Amy Braun2Andrea Auther3Monica E. Calkins4Barbara A. Cornblatt5Cheryl M. Corcoran6Paolo Fusar-Poli7Melissa J. Kerr8Catalina V. Mourgues-Codern9Angela R. Nunez10Dominic Oliver11Gregory P. Strauss12Barbara C. Walsh13Luis K. Alameda14Celso Arango15Nicholas J. K. Breitborde16Matthew R. Broome17Kristin S. Cadenhead18Ricardo E. Carrion19Eric Yu Hai Chen20Jimmy Choi21Michael J. Coleman22Philippe Conus23Covadonga M. Diaz-Caneja24Dominic Dwyer25Lauren M. Ellman26Masoomeh Faghankhani27Pablo A. Gaspar28Carla Gerber29Louise Birkedal Glenthøj30Leslie E. Horton31Christy Hui32Grace R. Jacobs33Joseph Kambeitz34Lana Kambeitz-Ilankovic35Matcheri S. Keshavan36Sung-Wan Kim37Nikolaos Koutsouleris38Jun Soo Kwon39Kerstin Langbein40Kathryn E. Lewandowski41Daniel Mamah42Patricia J. Marcy43Daniel H. Mathalon44Vijay A. Mittal45Merete Nordentoft46Godfrey D. Pearlson47Nora Penzel48Jesus Perez49Diana O. Perkins50Albert R. Powers51Jack Rogers52Fred W. Sabb53Jason Schiffman54Jai L. Shah55Steven M. Silverstein56Stefan Smesny57William S. Stone58Andrew Thompson59Judy L. Thompson60Rachel Upthegrove61Swapna Verma62Jijun Wang63Heather M. Wastler64Alana Wickham65Inge Winter-van Rossum66Daniel H. Wolf67Sylvain Bouix68Ofer Pasternak69Rene S. Kahn70Carrie E. Bearden71John M. Kane72Patrick D. McGorry73Kate Buccilli74Barnaby Nelson75Martha E. Shenton76Scott W. Woods77the Accelerating Medicines Partnership® -SchizophreniaAlison R. Yung78Department of Psychiatry, Hotchkiss Brain Institute, University of CalgaryDepartment of Psychiatry, Hotchkiss Brain Institute, University of CalgaryDepartment of Psychiatry, Hotchkiss Brain Institute, University of CalgaryDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineDepartment of Psychiatry, Perelman School of Medicine, University of PennsylvaniaDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineDepartment of Psychiatry, Icahn School of Medicine at Mount SinaiDepartment of Psychosis Studies, King’s CollegeOrygenDepartment of Psychiatry, Yale University School of MedicineDepartment of Psychiatry, Yale University School of MedicineDepartment of Psychosis Studies, King’s CollegeDepartment of Psychology, University of GeorgiaDepartment of Psychiatry, Yale University School of MedicineDepartment of Psychosis Studies, King’s CollegeDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad ComplutenseDepartment of Psychiatry and Behavioral Health, Ohio State UniversityInstitute for Mental Health, University of BirminghamUniversity of CaliforniaDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineNanyang Technological University, LKC School of MedicineOlin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health NetworkDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolService de Psychiatrie Générale Dép. de Psychiatrie CHUV LausanneDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad ComplutenseOrygenDepartment of Psychology & Neuroscience, Temple UniversityDepartment of Psychiatry, Washington University School of MedicineDepartment of Psychiatry, IMHAY, University of ChilePrevention Science Institute, University of OregonCopenhagen Research Centre for Mental Health, Mental Health Copenhagen, Department of Psychology, University of CopenhagenDepartment of Psychiatry, University of Pittsburgh School of MedicineDepartment of Psychiatry, University of Hong KongDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolUniversity of Cologne, Faculty of Medicine and University Hospital of CologneUniversity of Cologne, Faculty of Medicine and University Hospital of CologneBeth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Psychiatry, Chonnam National University Medical SchoolDepartment of Psychosis Studies, King’s CollegeDepartment of Psychiatry, Seoul National University College of MedicineDepartment of Psychiatry and Psychotherapy, Jena University HospitalDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolDepartment of Psychiatry, Washington University School of MedicineDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineDepartment of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San FranciscoDepartment of Psychology, Northwestern UniversityMental Health Services in the Capital RegionDepartment of Psychiatry, Yale University School of MedicineDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolCAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation TrustDepartment of Psychiatry, University of North CarolinaDepartment of Psychiatry, Yale University School of MedicineInstitute for Mental Health, University of BirminghamDepartment of Psychiatry, IMHAY, University of ChileDepartment of Psychological Science, University of CaliforniaPEPP-Montreal, Douglas Research CentreDepartment of Psychiatry, University of Rochester Medical CenterDepartment of Psychiatry and Psychotherapy, Jena University HospitalBeth Israel Deaconess Medical Center, Harvard Medical SchoolOrygenDepartment of Psychiatry, University of Rochester Medical CenterEarly Intervention for Psychosis Service, Birmingham Women’s and Children’s NHS Foundation TrustInstitute of Mental HealthShanghai Mental Health Center, Shanghai Jiaotong University School of MedicineDepartment of Psychiatry and Behavioral Health, Ohio State UniversityDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolDepartment of Psychosis Studies, King’s CollegeDepartment of Psychiatry, Perelman School of Medicine, University of PennsylvaniaDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolDepartment of Psychiatry, Icahn School of Medicine at Mount SinaiDepartments of Psychiatry and Biobehavioral Sciences & Psychology, Semel Institute for Neuroscience and Human Behavior, University of CaliforniaDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineOrygenOrygenOrygenDepartment of Psychiatry, Brigham and Women’s Hospital and Harvard Medical SchoolDepartment of Psychiatry, Yale University School of MedicineInstitute of Mental and Physical Health and Clinical Translation (IMPACT), Deakin UniversityAbstract Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Measures Team aimed to establish a harmonized clinical assessment protocol across these two research networks and to define ascertainment criteria and primary and secondary endpoints. In addition to developing the assessment protocol, the goals of this aspect of the AMP SCZ project were: (1) to implement and monitor clinical training, ascertainment of participants, and clinical assessments; (2) to provide expert clinical input to the Psychosis Risk Evaluation, Data Integration and Computational Technologies: Data Processing, Analysis, and Coordination Center (PREDICT-DPACC) for data collection, quality control, and preparation of data for the analysis of the clinical measures; and (3) to provide ongoing support to the collection, analysis, and reporting of clinical data. This paper describes the (1) protocol clinical endpoints and outcomes, (2) rationale for the selection of the clinical measures, (3) extensive training of clinical staff, (4) preparation of clinical measures for a multisite study which includes several sites where English is not the native language; and (5) the assessment of measure stability over time in the AMP SCZ observational study comparing clinical ratings at baseline and at the 2-month follow up. Watch Dr. Jean Addington discuss her work and this article: https://vimeo.com/1040425281 .https://doi.org/10.1038/s41537-025-00556-7 |
| spellingShingle | Jean Addington Lu Liu Amy Braun Andrea Auther Monica E. Calkins Barbara A. Cornblatt Cheryl M. Corcoran Paolo Fusar-Poli Melissa J. Kerr Catalina V. Mourgues-Codern Angela R. Nunez Dominic Oliver Gregory P. Strauss Barbara C. Walsh Luis K. Alameda Celso Arango Nicholas J. K. Breitborde Matthew R. Broome Kristin S. Cadenhead Ricardo E. Carrion Eric Yu Hai Chen Jimmy Choi Michael J. Coleman Philippe Conus Covadonga M. Diaz-Caneja Dominic Dwyer Lauren M. Ellman Masoomeh Faghankhani Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Hui Grace R. Jacobs Joseph Kambeitz Lana Kambeitz-Ilankovic Matcheri S. Keshavan Sung-Wan Kim Nikolaos Koutsouleris Jun Soo Kwon Kerstin Langbein Kathryn E. Lewandowski Daniel Mamah Patricia J. Marcy Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Nora Penzel Jesus Perez Diana O. Perkins Albert R. Powers Jack Rogers Fred W. Sabb Jason Schiffman Jai L. Shah Steven M. Silverstein Stefan Smesny William S. Stone Andrew Thompson Judy L. Thompson Rachel Upthegrove Swapna Verma Jijun Wang Heather M. Wastler Alana Wickham Inge Winter-van Rossum Daniel H. Wolf Sylvain Bouix Ofer Pasternak Rene S. Kahn Carrie E. Bearden John M. Kane Patrick D. McGorry Kate Buccilli Barnaby Nelson Martha E. Shenton Scott W. Woods the Accelerating Medicines Partnership® -Schizophrenia Alison R. Yung Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program Schizophrenia |
| title | Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program |
| title_full | Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program |
| title_fullStr | Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program |
| title_full_unstemmed | Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program |
| title_short | Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program |
| title_sort | sample ascertainment and clinical outcome measures in the accelerating medicines partnership r schizophrenia program |
| url | https://doi.org/10.1038/s41537-025-00556-7 |
| work_keys_str_mv | AT jeanaddington sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT luliu sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT amybraun sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT andreaauther sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT monicaecalkins sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT barbaraacornblatt sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT cherylmcorcoran sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT paolofusarpoli sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT melissajkerr sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT catalinavmourguescodern sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT angelarnunez sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT dominicoliver sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT gregorypstrauss sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT barbaracwalsh sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT luiskalameda sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT celsoarango sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT nicholasjkbreitborde sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT matthewrbroome sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT kristinscadenhead sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT ricardoecarrion sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT ericyuhaichen sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT jimmychoi sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT michaeljcoleman sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT philippeconus sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT covadongamdiazcaneja sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT dominicdwyer sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT laurenmellman sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT masoomehfaghankhani sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT pabloagaspar sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT carlagerber sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT louisebirkedalglenthøj sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT leslieehorton sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT christyhui sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT gracerjacobs sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT josephkambeitz sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT lanakambeitzilankovic sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT matcheriskeshavan sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT sungwankim sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT nikolaoskoutsouleris sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT junsookwon sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT kerstinlangbein sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT kathrynelewandowski sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT danielmamah sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT patriciajmarcy sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT danielhmathalon sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT vijayamittal sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT meretenordentoft sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT godfreydpearlson sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT norapenzel sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT jesusperez sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT dianaoperkins sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT albertrpowers sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT jackrogers sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT fredwsabb sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT jasonschiffman sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT jailshah sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT stevenmsilverstein sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT stefansmesny sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT williamsstone sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT andrewthompson sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT judylthompson sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT rachelupthegrove sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT swapnaverma sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT jijunwang sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT heathermwastler sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT alanawickham sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT ingewintervanrossum sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT danielhwolf sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT sylvainbouix sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT oferpasternak sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT reneskahn sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT carrieebearden sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT johnmkane sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT patrickdmcgorry sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT katebuccilli sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT barnabynelson sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT marthaeshenton sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT scottwwoods sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT theacceleratingmedicinespartnershipschizophrenia sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram AT alisonryung sampleascertainmentandclinicaloutcomemeasuresintheacceleratingmedicinespartnershipschizophreniaprogram |